Albert David Ltd

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 8 June 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and unfavourable valuation metrics, signalling heightened risk for investors in the stock currently trading at ₹696.40.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Albert David Ltd., a Kolkata-based pharmaceutical manufacturer under the Kothari Group, reported a startling quarterly loss of ₹21.43 crores for Q4 FY26, marking a dramatic reversal from the ₹15.30 crore profit posted in the previous quarter. The unexpected downturn, representing a 107.50% quarter-on-quarter decline, has sent the stock tumbling 7.74% to ₹716.00, erasing gains and pushing the micro-cap pharma company deeper into valuation concerns.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

A sharp decline has pushed Albert David Ltd to a fresh 52-week low of Rs 598.25, marking a significant 37.6% drop from its 52-week high of Rs 959.35. This downturn comes amid a broader market weakness, but the stock’s underperformance is notably more severe than the benchmark indices.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.601 today, marking a significant decline amid ongoing market headwinds and subdued financial performance over the past year.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Albert David Ltd’s share price declined sharply to a new 52-week low of Rs.645 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in financial performance and market sentiment.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of its performance and outlook.

Albert David Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Albert David Ltd., a Kolkata-based pharmaceutical manufacturer, reported a net loss of ₹3.30 crores in Q2 FY26 (Jul-Sep'25), marking a sharp reversal from the ₹18.07 crores profit posted in the same quarter last year—a staggering decline of 118.27% year-on-year. The loss comes despite a modest sequential recovery in the previous quarter, highlighting persistent operational challenges that have plagued the company throughout FY25 and into FY26.